New contraindication against using darunavir/cobicistat during pregnancy
29 June 2018. Related: Treatment alerts, Antiretrovirals.
Treatment alerts
Janssen Dear Doctor letter: Prezista (darunavir), Rezolsta ▼(darunavir/cobicistat)and Symtuza ▼(darunavir/cobicistat/emtricitabine/tenofovir alafenamide)
29 June 2018. Related: Treatment alerts, Pregnancy.
BHIVA statement on potential safety signal in infants born to women conceiving on dolutegravir
8 June 2018. Related: Treatment alerts, Pregnancy, Side effects.
ViiV Dear Doctor letter: Neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception
8 June 2018. Related: Treatment alerts, Pregnancy.
Potential safety signal for dolutegravir from the time of conception
21 May 2018. Related: Treatment alerts, Pregnancy.
Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs
26 June 2017. Related: Treatment alerts, Antiretrovirals, Side effects.
NHS England confuses arse and elbow: block to PrEP ignores UK HIV crisis and will send PEP services into chaos
2 June 2016. Related: Treatment alerts, Treatment access, HIV prevention and transmission.
Early START results recommend ART for all study participants: starting HIV meds when the CD4 count is above 500 reduces AIDS-related events
1 June 2015. Related: Treatment alerts.
ARV supply issues cause treatment interruptions in a UK clinic
1 December 2014. Related: Treatment alerts.
CROI website still blocked
1 October 2013. Related: Treatment alerts.
WHO statement: generic antiretroviral therapy is safe and effective
1 February 2013. Related: Treatment alerts, Antiretrovirals.
Tibotec issues Dear Doctor letter in Europe concerning severe etravirine reactions: three case reports
30 December 2009. Related: Treatment alerts, Antiretrovirals.
Update on nelfinavir recall: plan for safety registries
3 September 2007. Related: Treatment alerts.
Pfizer issue Dear Doctor letter over EMS content in US formulation of nelfinavir
3 September 2007. Related: Treatment alerts.
Roche recalls nelfinavir (Viracept) due to chemical impurity
10 July 2007. Related: Treatment alerts.
European Medicines Agency press release on the nelfinavir recall
7 July 2007. Related: Treatment alerts.
Notification of product recall due to Class 1 drug alert
7 July 2007. Related: Treatment alerts.
EMEA questions and answers on the nelfinavir recall
7 July 2007. Related: Treatment alerts.
Dear Doctor letter issued in the U.S. relating to 14 reports of intracranial haemorrhage (ICH) events with tipranavir/r
3 August 2006. Related: Treatment alerts.
Important renal safety information regarding the use of tenofovir and Truvada
13 April 2006. Related: Treatment alerts.
Drug-induced hepatitis in healthy volunteers receiving rifampicin 600mg daily in combination with ritonavir 100mg and saquinavir 1000mg twice daily (boosted saquinavir)
18 April 2005. Related: Treatment alerts.
New European recommendations regarding the co-administration of ddI (Videx) and tenofovir DF (Viread)
18 April 2005. Related: Treatment alerts.
Important new pharmacokinetic data demonstrating that atazanavir sulfate (Reyataz) combined with ritonavir (Norvir) and proton pump inhibitors should not be coadministered
29 March 2005. Related: Treatment alerts.
Important new clinical data: potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine, and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads
31 January 2005. Related: Treatment alerts.
A round-up of news about access to treatments, with links to sources
29 July 2004. Related: Treatment alerts.
Risk factors for severe, life-threatening and fatal hepatotoxicity with nevirapine
3 April 2004. Related: Treatment alerts.
Important safety information: high rate of virologic failure in patients with HIV infection treated with a once-daily triple NRTI combination containing ddI, 3TC, and tenofovir DF
1 November 2003. Related: Treatment alerts.
Important new pharmacokinetic data for atazanavir sulfate (Reyataz) in combination with tenofovir disoproxil fumarate (Viread)
1 October 2003. Related: Treatment alerts.
EMEA public statement on early virologic non-response in patients with HIV infection treated with tenofovir in combination with lamivudine and abacavir
1 September 2003. Related: Treatment alerts.
New safety information for ddI used with ribavirin
13 November 2002. Related: Treatment alerts, Antiretrovirals.
US FDA issues new safety information for tenofovir co-administration with ddI
13 November 2002. Related: Treatment alerts, Antiretrovirals.
BMS advice on interaction between didanosine EC and tenofovir
11 July 2002. Related: Treatment alerts, Antiretrovirals.
Rapidly ascending neuromuscular weakness associated with nucleoside analogues
2 October 2001. Related: Treatment alerts, Side effects.
Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures – worldwide, 1997-2000
17 January 2001. Related: Treatment alerts.
US FDA and Bristol-Myers Squibb issue caution for combination HIV therapy with stavudine (d4T) and didanosine (ddI) in pregnant women
17 January 2001. Related: Treatment alerts, Women's health, Pregnancy.
Abacavir hypersensitivity cases following an interruption of therapy
16 September 2000. Related: Treatment alerts.
Severe Hypersensitivity Reactions following reintroduction with Ziagen (abacavir sulphate)
16 August 2000. Related: Treatment alerts.
Safety warning on amprenavir oral liquid
15 June 2000. Related: Treatment alerts.